DK1800134T3 - Fremgangsmåde til diagnosticering og behandling af Chron's sygdom - Google Patents

Fremgangsmåde til diagnosticering og behandling af Chron's sygdom

Info

Publication number
DK1800134T3
DK1800134T3 DK05809109T DK05809109T DK1800134T3 DK 1800134 T3 DK1800134 T3 DK 1800134T3 DK 05809109 T DK05809109 T DK 05809109T DK 05809109 T DK05809109 T DK 05809109T DK 1800134 T3 DK1800134 T3 DK 1800134T3
Authority
DK
Denmark
Prior art keywords
disease
diagnosing
chron
treating
crohn
Prior art date
Application number
DK05809109T
Other languages
English (en)
Inventor
Nicolas Barnich
Arlette Darfeuille-Michaud
Anne-Lise Glasser
Original Assignee
Univ Clermont Auvergne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Clermont Auvergne filed Critical Univ Clermont Auvergne
Application granted granted Critical
Publication of DK1800134T3 publication Critical patent/DK1800134T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DK05809109T 2004-10-14 2005-10-13 Fremgangsmåde til diagnosticering og behandling af Chron's sygdom DK1800134T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0410865A FR2876798A1 (fr) 2004-10-14 2004-10-14 Diagnostic et traitement de la maladie de crohn
PCT/FR2005/002538 WO2006040481A2 (fr) 2004-10-14 2005-10-13 Procede de diagnostic et traitement de la maladie de crohn

Publications (1)

Publication Number Publication Date
DK1800134T3 true DK1800134T3 (da) 2009-03-16

Family

ID=34951162

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05809109T DK1800134T3 (da) 2004-10-14 2005-10-13 Fremgangsmåde til diagnosticering og behandling af Chron's sygdom

Country Status (10)

Country Link
US (2) US9176131B2 (da)
EP (1) EP1800134B1 (da)
JP (1) JP4896883B2 (da)
AT (1) ATE415632T1 (da)
CA (1) CA2582228C (da)
DE (1) DE602005011316D1 (da)
DK (1) DK1800134T3 (da)
ES (1) ES2317327T3 (da)
FR (1) FR2876798A1 (da)
WO (1) WO2006040481A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377883A1 (en) 2010-04-15 2011-10-19 Universite d'Auvergne Clermont I Antagonists for the prevention or treatment of inflammatory bowel disease, and more particularly of Crohn's disease
ES2732311T3 (es) 2011-02-07 2019-11-21 Univ Washington Compuestos de manósidos y procedimientos de uso de los mismos
EP2935302B1 (en) 2012-12-18 2018-06-06 Vertex Pharmaceuticals Incorporated Mannose derivatives for treating bacterial infections
MX2015012472A (es) 2013-03-12 2016-02-10 Vertex Pharma Derivados de manosa para el tratamiento de infecciones bacterianas.
EP3003322B1 (en) * 2013-05-30 2023-09-13 Washington University Mannose derivatives and their use in the treatment of bacterial infections
CN104459154B (zh) * 2014-12-09 2016-04-27 临沂大学 一种新型人工模拟酶的合成及对糖基检测方法的构建
US10738070B2 (en) 2016-03-23 2020-08-11 Fimbrion Therapeutics, Inc. Mannose-derived antagonists of FimH useful for treating disease
KR102373502B1 (ko) * 2018-05-14 2022-03-11 주식회사 금호에이치티 골수유래억제세포 관련 질환의 예방 및 치료 용도
SG11202011066XA (en) 2018-07-10 2021-01-28 Glaxosmithkline Ip Dev Ltd C-mannoside compounds useful for the treatment of urinary tract infections
EP3757572A1 (en) * 2019-06-27 2020-12-30 Centre National de la Recherche Scientifique Detection of pathogenic bacteria by chemically functionalized cellulose

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308838A (en) * 1982-05-07 1994-05-03 Carrington Laboratories, Inc. Uses of aloe products
JP3342749B2 (ja) * 1993-09-20 2002-11-11 積水化学工業株式会社 糖化蛋白の測定方法
EP0747705A1 (en) * 1995-06-09 1996-12-11 Bayer Corporation Specific determination of NCA 90 glycoform in the blood of cancer patients
WO1997018790A2 (en) * 1995-11-22 1997-05-29 The Research And Development Institute, Inc. Therapeutic and diagnostic agents for the treatment of microbial infections
US5874233A (en) 1996-04-12 1999-02-23 Cedars-Sinai Medical Center Methods of diagnosing a clinical subtype of Crohn's disease with features of ulcerative colitis
US6290959B1 (en) * 1996-10-24 2001-09-18 New York University Method for screening compounds for inhibiting bacterial attachment to host cell receptors
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
US6942981B1 (en) * 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US7138237B1 (en) * 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
EP1381688A1 (en) * 2001-04-25 2004-01-21 N.V. Nutricia Process for the manufacture of a fermented health-promoting product
JP4947851B2 (ja) * 2001-06-07 2012-06-06 信紘 佐藤 潰瘍性大腸炎治療薬
AU2002313458A1 (en) * 2001-06-29 2003-03-03 Astion Development A/S Niaciamide and derivatives in combination with aminosugar
WO2003070266A1 (en) * 2001-10-12 2003-08-28 Mount Sinai School Of Medicine Enhanced immunization and suppression of oral tolerance
US20040005304A1 (en) * 2002-07-08 2004-01-08 Mak Wood, Inc. Novel compositions and methods for treating neurological disorders and associated gastrointestinal conditions
US8247231B2 (en) * 2003-07-31 2012-08-21 Wilson Constance N Methods and compositions for producing antigenic responses
US7799328B2 (en) * 2004-12-23 2010-09-21 Biocodex Method for treating weight loss in patients suffering from inflammatory bowel diseases
ES2649914T3 (es) * 2007-12-26 2018-01-16 Lesaffre Et Compagnie Composición para la alimentación humana y/o animal, sus usos, levaduras

Also Published As

Publication number Publication date
ATE415632T1 (de) 2008-12-15
JP4896883B2 (ja) 2012-03-14
FR2876798A1 (fr) 2006-04-21
ES2317327T3 (es) 2009-04-16
WO2006040481A2 (fr) 2006-04-20
WO2006040481A3 (fr) 2006-08-31
EP1800134B1 (fr) 2008-11-26
JP2008517261A (ja) 2008-05-22
CA2582228A1 (fr) 2006-04-20
US20100015600A1 (en) 2010-01-21
CA2582228C (fr) 2018-07-31
US20160091501A1 (en) 2016-03-31
US9176131B2 (en) 2015-11-03
EP1800134A2 (fr) 2007-06-27
DE602005011316D1 (de) 2009-01-08

Similar Documents

Publication Publication Date Title
DK1800134T3 (da) Fremgangsmåde til diagnosticering og behandling af Chron's sygdom
CY1118566T1 (el) Διαγνωση με χρηση ιντερφερονης τυπου 1
WO2008070137A3 (en) Interferon alpha-induced pharmacodynamic markers
CY1125258T1 (el) Νεοι παραγοντες απεικονισης για ανιχνευση νευρολογικης δυσλειτουργιας
EA200971131A1 (ru) Биомаркеры для прогнозирования чувствительности или отсутствия чувствительности к анти-фно агентам
DK1493439T3 (da) Middel til fastlæggelse af en persons risikoprofil for aterosklerotisk sygdom
TW200605907A (en) Preventing autoimmune disease
DK1530724T3 (da) Diagnose og forebyggelse af cancercelleinvasion
BR0213846A (pt) métodos de induzir seletivamente a apoptose nas células alvo que expressam dr5, de inibir a proliferação de células alvo que expressam dr5 e de tratar um paciente tendo uma doença inflamatória ou doença autoimune, e, composição
PT1318837E (pt) Metodo de tratamenton de carcinoma positivo a receptor de estrogenio
MX2007004176A (es) B7-h1 y metodos de diagnosis, prognosis, y tratamiento de cancer.
AU2003263603A8 (en) Method for diagnosing pancreatic cancer
RS20050035A (en) Therapies for renal failure using interferon-betha
EA200500232A1 (ru) Способы диагностики и лечения преэклампсии или эклампсии
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
WO2008030273A3 (en) Compositions and methods for diagnosis and treatment of type 2 diabetes
HK1069767A1 (en) Methods for inhibiting ocular processes
WO2008118148A3 (en) Adiponectin for the treatment and diagnosis of albuminuria
DK1075277T3 (da) Fremgangsmåder til detektion og inhibering af angiogenese
EP1953549A4 (en) ASBESTAN PROCEDURE, ASBESTAN DETERGENT, ASBESTAT PROTECTION KIT, AND METHOD FOR SEARCHING FOR CANDIDATES FOR A MEDICAMENT TO PREVENT OR TREAT ANY DISEASE OR CLAIMED ASBEST DISEASE
DE60137264D1 (de) Monoklonale antikörper und zelloberflächenantigene zum nachweis und zur behandlung von kleinzelligem lungenkrebs (sclc)
ATE530667T1 (de) Kcnn3 als diagnostisches und therapeutisches target für alzheimer-krankheit
SG163614A1 (en) Colon cancer related gene tom34
BRPI0409562A (pt) tratamento de condições envolvendo placas amilóides
ATE529750T1 (de) Stimulatorische autoantikörper gegen den pdgf- rezeptor als pathologische marker und therapeutisches target